Condition: Neovascular Age-related Macular Degeneration · Sponsor: AbbVie
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide. Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Barnet Dulaney Perkins Eye Centers /ID# 279265 | Mesa, Arizona, United States | Recruiting |
| American Vision Partners /ID# 264615 | Sun City, Arizona, United States | Recruiting |
| Retinal Diagnostic Center /ID# 263054 | Campbell, California, United States | Recruiting |
| The Retina Partners /ID# 263265 | Encino, California, United States | Recruiting |
| Retina Associates of Southern California /ID# 263056 | Huntington Beach, California, United States | Recruiting |
| Northern California Retina Vitreous Associates - Mountain View /ID# 263990 | Mountain View, California, United States | Recruiting |
| Retina Consultants of San Diego /ID# 264026 | Poway, California, United States | Recruiting |
| Retina Consultants Of Southern California - Redlands /ID# 276496 | Redlands, California, United States | Recruiting |
| Kaiser Permanente - Riverside Medical Center /ID# 263253 | Riverside, California, United States | Recruiting |
| Retinal Consultants - Sacramento - Greenback Lane /ID# 263983 | Sacramento, California, United States | Recruiting |
| UCSF, Wayne and Gladys Valley Center for Vision /ID# 263058 | San Francisco, California, United States | Recruiting |
| Orange County Retina Medical Group /ID# 266612 | Santa Ana, California, United States | Recruiting |
+ 117 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07007065